Toxic deaths during treatment were 9 with BV-AVD [7/9 due to febrile neutropenia in patients not receiving primary Granulocyte Colony Stimulating Factor (G-CSF) prophylaxis] vs. 13 during ABVD (11/13 due to pulmonary toxicity, probably bleomycin-related) for an overall toxic death rate of 1.4% vs. 1.9%. This evidence concerns the gene CSF3 and neutropenia.